334 related articles for article (PubMed ID: 24196484)
1. Transforming growth factor-β signalling controls human breast cancer metastasis in a zebrafish xenograft model.
Drabsch Y; He S; Zhang L; Snaar-Jagalska BE; ten Dijke P
Breast Cancer Res; 2013 Nov; 15(6):R106. PubMed ID: 24196484
[TBL] [Abstract][Full Text] [Related]
2. Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
Spender LC; Ferguson GJ; Liu S; Cui C; Girotti MR; Sibbet G; Higgs EB; Shuttleworth MK; Hamilton T; Lorigan P; Weller M; Vincent DF; Sansom OJ; Frame M; Dijke PT; Marais R; Inman GJ
Oncotarget; 2016 Dec; 7(50):81995-82012. PubMed ID: 27835901
[TBL] [Abstract][Full Text] [Related]
3. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
Bhola NE; Balko JM; Dugger TC; Kuba MG; Sánchez V; Sanders M; Stanford J; Cook RS; Arteaga CL
J Clin Invest; 2013 Mar; 123(3):1348-58. PubMed ID: 23391723
[TBL] [Abstract][Full Text] [Related]
4. Genetic depletion and pharmacological targeting of αv integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models.
Li Y; Drabsch Y; Pujuguet P; Ren J; van Laar T; Zhang L; van Dam H; Clément-Lacroix P; Ten Dijke P
Breast Cancer Res; 2015 Feb; 17(1):28. PubMed ID: 25849225
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor.
Bandyopadhyay A; Agyin JK; Wang L; Tang Y; Lei X; Story BM; Cornell JE; Pollock BH; Mundy GR; Sun LZ
Cancer Res; 2006 Jul; 66(13):6714-21. PubMed ID: 16818646
[TBL] [Abstract][Full Text] [Related]
6. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
Park CY; Kim DK; Sheen YY
Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
[TBL] [Abstract][Full Text] [Related]
7. Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis.
Petersen M; Pardali E; van der Horst G; Cheung H; van den Hoogen C; van der Pluijm G; Ten Dijke P
Oncogene; 2010 Mar; 29(9):1351-61. PubMed ID: 20010874
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Wendt MK; Schiemann WP
Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
[TBL] [Abstract][Full Text] [Related]
9. Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells.
Zhang J; Thorikay M; van der Zon G; van Dinther M; Ten Dijke P
J Vis Exp; 2020 Oct; (164):. PubMed ID: 33191940
[TBL] [Abstract][Full Text] [Related]
10. Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.
Zhang L; Zhou D; Guan W; Ren W; Sun W; Shi J; Lin Q; Zhang J; Qiao T; Ye Y; Wu Y; Zhang Y; Zuo X; Connor KL; Xu G
Cell Death Dis; 2017 Dec; 8(12):3214. PubMed ID: 29238081
[TBL] [Abstract][Full Text] [Related]
11. Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor beta type I receptor.
Burch ML; Ballinger ML; Yang SNY; Getachew R; Itman C; Loveland K; Osman N; Little PJ
J Biol Chem; 2010 Aug; 285(35):26798-26805. PubMed ID: 20571025
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.
Ganapathy V; Ge R; Grazioli A; Xie W; Banach-Petrosky W; Kang Y; Lonning S; McPherson J; Yingling JM; Biswas S; Mundy GR; Reiss M
Mol Cancer; 2010 May; 9():122. PubMed ID: 20504320
[TBL] [Abstract][Full Text] [Related]
13. Distinct roles of transforming growth factor-β signaling and transforming growth factor-β receptor inhibitor SB431542 in the regulation of p21 expression.
Koo BH; Kim Y; Je Cho Y; Kim DS
Eur J Pharmacol; 2015 Oct; 764():413-423. PubMed ID: 26187313
[TBL] [Abstract][Full Text] [Related]
14. The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system.
Wiercinska E; Naber HP; Pardali E; van der Pluijm G; van Dam H; ten Dijke P
Breast Cancer Res Treat; 2011 Aug; 128(3):657-66. PubMed ID: 20821046
[TBL] [Abstract][Full Text] [Related]
15. TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer.
Busch S; Acar A; Magnusson Y; Gregersson P; Rydén L; Landberg G
Oncogene; 2015 Jan; 34(1):27-38. PubMed ID: 24336330
[TBL] [Abstract][Full Text] [Related]
16. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Melisi D; Ishiyama S; Sclabas GM; Fleming JB; Xia Q; Tortora G; Abbruzzese JL; Chiao PJ
Mol Cancer Ther; 2008 Apr; 7(4):829-40. PubMed ID: 18413796
[TBL] [Abstract][Full Text] [Related]
17. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers.
Halder SK; Beauchamp RD; Datta PK
Neoplasia; 2005 May; 7(5):509-21. PubMed ID: 15967103
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta-mediated activation of RhoA signalling is required for efficient (V12)HaRas and (V600E)BRAF transformation.
Fleming YM; Ferguson GJ; Spender LC; Larsson J; Karlsson S; Ozanne BW; Grosse R; Inman GJ
Oncogene; 2009 Feb; 28(7):983-93. PubMed ID: 19079344
[TBL] [Abstract][Full Text] [Related]
19. Transforming Growth Factor-β Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion.
Gupta S; Hau AM; Al-Ahmadie HA; Harwalkar J; Shoskes AC; Elson P; Beach JR; Hussey GS; Schiemann WP; Egelhoff TT; Howe PH; Hansel DE
Am J Pathol; 2016 May; 186(5):1351-60. PubMed ID: 26988652
[TBL] [Abstract][Full Text] [Related]
20. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
